Overview of Actraphane

Property	Description
Active Ingredient	Human insulin (Insulinum humanum)
Form	Suspension for injection
Pharmacological Class	Antidiabetic agent; Biphasic insulin
General Purpose	Comprehensive blood glucose management
Origin	Biosynthetic (Recombinant DNA technology)

What Type of Medicine is Actraphane and Its Origin?

Actraphane is a prescription-only biphasic insulin formulation, which is clinically recognized for providing dual-acting blood sugar control. It belongs to the antidiabetic agent class. The active component is recombinant human insulin (Insulinum humanum), a molecule structurally identical to the insulin naturally produced by the human body. This insulin is manufactured through biosynthetic processes utilizing recombinant DNA technology. Actraphane is supplied as a suspension for injection intended for subcutaneous administration, typically used in adults and children requiring a blend of rapid and intermediate insulin effects.

What is Biphasic Human Insulin Made Of?

Actraphane is a fixed-ratio combination product that merges two distinct types of human insulin into a single injectable suspension. It consists of Soluble human insulin, which serves as the fast-acting component, and Isophane human insulin (NPH), which is the intermediate-acting component. The Isophane form is created by complexing the soluble insulin with protamine to delay its absorption and prolong its action. Insulin products help the body effectively utilize blood sugar. The various fixed ratios (e.g., Actraphane 30, 40, or 50) are a differentiating feature, allowing healthcare professionals to tailor the balance of rapid and intermediate action profiles.

What is the General Purpose of Dual-Acting Insulin?

The general therapeutic purpose of this dual-acting structure is to provide comprehensive blood glucose control with a single product. Actraphane provides a rapid component for immediate glucose uptake stimulation following a meal and a delayed, intermediate component for sustained glucose control between meals and overnight. This complementary action helps stabilize overall blood sugar profiles throughout the day, mitigating the risks associated with consistently elevated glucose levels in individuals with diabetes mellitus.

Regulatory References

What side effects are possible with Actraphane?

Possible Side Effects and Safety Information

Adverse reactions associated with this biphasic human insulin formulation are organized and classified by regulatory bodies based on frequency and affected body system. Hypoglycaemia (low blood sugar) is designated as the most frequently reported adverse reaction and is classified as Very Common.

Less frequent adverse reactions, categorized as Uncommon, involve general and localized issues such as temporary oedema (fluid retention), lipodystrophy (changes in fat tissue), and various injection site reactions (e.g., pain, redness, swelling). Additionally, temporary changes in vision (refraction disorders) and acute painful neuropathy (nerve pain) have been reported in this frequency tier.

Regulatory Classification of Adverse Reactions

System-Organ Class	Very Common	Uncommon	Very Rare
Metabolism and nutrition disorders	Hypoglycaemia
Skin and subcutaneous tissue disorders		Lipodystrophy
General disorders and admin. site conditions		Injection site reactions, Oedema
Immune system disorders		Urticaria, rash	Generalised hypersensitivity, Anaphylactic reactions

Serious Adverse Reactions and Safety Considerations

The regulatory profile identifies Severe Hypoglycaemia as the most critical risk, which can potentially lead to unconsciousness or temporary brain impairment. Rare, but potentially life-threatening, Generalised Hypersensitivity/Anaphylactic Reactions are also documented.

Safety notes for specific populations state that insulin dose requirements may change for individuals with renal or hepatic impairment and during pregnancy. Furthermore, continuous rotation of the injection site is a safety measure explicitly required in labeling to reduce the risk of tissue reactions like lipodystrophy.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with Actraphane (human insulin) results in hypoglycemia, or excessively low blood glucose, which forms the core of the official regulatory overdose profile. The entire clinical course and required emergency response are defined by this metabolic imbalance.

Documented Manifestations

Symptoms documented in the official prescribing information for initial-stage hypoglycemia typically include cold sweats, tremor, confusion, unusual tiredness, palpitation, and headache. These signs serve as the trigger for immediate intervention.

Severe Outcomes and Emergency Action

Untreated or severe overdosage can rapidly escalate to severe hypoglycemia, a medical emergency that may lead to convulsions and unconsciousness. Regulatory sources document the potential for temporary or permanent impairment of brain function if this state is not corrected.

For severe manifestations, the regulatory instruction mandates the immediate administration of a glucagon injection (subcutaneously or intramuscularly) and subsequently seeking immediate medical attention at a hospital or emergency facility. If the patient is unconscious, symptomatic and supportive treatment involves the administration of an intravenous glucose solution.

Official documentation notes that continuous monitoring, including blood glucose and plasma potassium levels, may be required. Furthermore, regulatory documents specify that patients with pre-existing renal or hepatic impairment may be at increased risk for overdosage severity.

Therapeutic Uses of Actraphane

What Actraphane Treats: Main Uses and Benefits

Actraphane (biphasic isophane insulin) is applied across domains of diabetes management to support functional stability when symptoms are more noticeable, and contributes to easing the overall symptom load. Its primary therapeutic indication is for the treatment of diabetes mellitus.

This medication helps address symptom clusters that may become intense or disruptive after eating, and is relevant for easing symptoms that may arise during phases of low physiological activity. It provides supportive relief when symptoms interfere with routine activities, which helps with managing symptoms that create noticeable physiological strain, such as excessive thirst, fatigue, and blurry vision. The medication is commonly used across conditions presenting with episodic or fluctuating manifestations in both Type 1 and Type 2 Diabetes when symptoms related to systemic imbalance are present.

“It provides support that helps ease the overall symptom burden and contributes to improved day-to-day comfort during periods of heightened symptoms.”

It is applied in clinical settings that involve acute or unstable symptom patterns, where additional management of discomfort helps support general well-being during symptomatic phases.

Quick Fact: Supports Easing Symptoms Linked to Systemic Imbalance

Assisting with Management of Symptom Clusters

This therapy is relevant for easing symptoms that may cause temporary functional strain or discomfort. It is used in settings where short-term symptom stabilization is important, helping to maintain a sense of stability when symptoms that interfere with daily functioning become more noticeable.

Regulatory References

European Medicines Agency (EMA) product information

Eligibility and Restrictions for Use

Actraphane eligibility is defined by official regulatory documents, which establish the permitted age groups, absolute contraindications, and populations requiring conditional use.

Eligibility scope

Eligibility scope	Official Regulatory Status
Populations for whom use is allowed	Adults; Paediatric population (children and adolescents).
Populations for whom use is contraindicated	Patients with known hypersensitivity to human insulin or any excipients.
Age-related eligibility rules	Elderly patients (ge 65 years) are permitted to use Actraphane, but require intensified glucose monitoring and individual dose adjustment.
Condition-specific eligibility rules	Patients with renal or hepatic impairment are eligible, but use requires intensified glucose monitoring and dose adjustment.
Pregnancy and lactation eligibility status	No restriction on treatment is documented for use during pregnancy or breastfeeding.

Eligibility-related restrictions

Actraphane must not be injected during actual or suspected episodes of hypoglycaemia (low blood glucose), as defined by official labeling. Concomitant illness (such as infections) is also stated to affect insulin requirements, necessitating adjustment.

Connection to the overall eligibility profile

Regulatory documents establish the entire age spectrum from children to the elderly as eligible, but restrict access based on Absolute Contraindications such as hypersensitivity. Eligibility is conditional upon mandatory intensified monitoring in populations with concurrent conditions like impaired kidney or liver function.

What should I know about interactions with other medicines?

Actraphane’s interaction profile focuses on pharmacodynamic effects that officially alter a patient’s need for insulin to maintain blood glucose control. Regulatory documents categorize interacting substances based on their effect on the patient's insulin requirement. No specific drug-drug combinations are listed as formally contraindicated interactions, nor are specific pharmacokinetic or transporter-mediated interactions documented.

Interaction Outcome	Examples of Interacting Medicinal Products
May Decrease Insulin Requirement (Risk of Hypoglycemia)	Oral antidiabetic medicines, Monoamine oxidase inhibitors (MAOI), non-selective beta-blocking agents, ACE inhibitors, Salicylates, Anabolic steroids, and Sulfonamides.
May Increase Insulin Requirement (Risk of Hyperglycemia)	Oral contraceptives, Thiazides, Glucocorticoids, Thyroid hormones, Sympathomimetics, Growth hormone, and Danazol.

Substances such as Octreotide or Lanreotide are documented to have a variable effect, potentially increasing or decreasing the required insulin dose. Additionally, the regulatory information notes that alcohol may variably intensify and prolong or, conversely, reduce the blood glucose-lowering action. An interaction-related constraint involves non-selective beta-blocking agents, which are officially documented to mask the usual symptoms a person experiences during hypoglycemia. No mandatory separation of doses is specified for co-administered medicines.

Mechanism of Action

Actraphane is a biphasic insulin formulation composed of soluble (rapid-acting) and isophane (intermediate-acting) insulin, both of which function as agonists of the insulin receptor (IR). The IR is a cell-surface tyrosine kinase receptor; its activation initiates an intracellular signaling cascade.

The soluble component is rapidly absorbed, causing a quick increase in circulating insulin concentration. This increase promotes the translocation of GLUT4 transporters from the cytoplasm to the plasma membrane of muscle and adipose cells, enhancing glucose uptake. Simultaneously, it modulates glycogen synthesis and suppresses hepatic glucose output by regulating key liver enzymes.

The intermediate-acting isophane component contains protamine and zinc, forming a complex that dictates slower absorption. This results in a sustained basal insulin concentration. The biphasic nature provides both a quick onset and a prolonged duration of action, influencing whole-body glucose clearance across various physiological periods.

Dosage and Administration Information

Administration of Actraphane

Actraphane is an insulin suspension intended for subcutaneous injection. It consists of a mixture of short-acting insulin and intermediate-acting insulin. Proper administration technique is necessary to ensure the medication is absorbed effectively and to maintain stable blood glucose levels.

Preparation for Use

Before administration, the insulin suspension must be brought to room temperature. The vial or pen should be rotated or rolled gently between the hands until the liquid appears uniformly white and cloudy. If the liquid contains clumps or if solid white particles stick to the bottom or wall of the container giving it a frosted appearance, the insulin should not be used.

Injection Site Selection

Common injection sites include the abdomen, the buttocks, the front of the thighs, or the upper arms. The rate of absorption may vary depending on the chosen site, with the abdominal wall typically providing the fastest absorption.

To reduce the risk of localized skin reactions or changes in the fatty tissue under the skin, such as thickening or pitting, it is important to rotate injection sites within a specific anatomical area. A new injection should always be at least one centimeter away from the previous injection site.

Handling and Delivery

Actraphane is designed for subcutaneous delivery only. It should not be administered intravenously or intramuscularly, as this can lead to severe hypoglycemia due to altered absorption rates.

When using a syringe or an insulin pen, the needle should remain under the skin for several seconds after the plunger has been fully depressed to ensure the full dose has been delivered. After the injection, the needle should be removed and disposed of safely. For safety and hygiene, needles and delivery devices must never be shared between individuals.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Actraphane

Evidence for Use in Managing Diabetes Mellitus

Research exploring how symptoms change over time in individuals with Diabetes Mellitus has primarily relied on short-term randomized controlled trials (RCTs) focusing on adults with Type 1 and Type 2 Diabetes. Investigators primarily measured outcomes related to systemic or functional imbalance (measured using HbA1c) and immediate biomarker shifts such as Fasting Plasma Glucose (FPG) and postprandial glucose (PPG).

Research describes that the measured changes in HbA1c in patients using biphasic human insulin showed patterns related to those observed when other human insulin treatments were studied. Findings from comparative studies with certain analogue insulins were mixed or data show patterns related to HbA1c values that were within a similar range across observed groups. Additionally, the occurrence of low blood sugar (hypoglycemia) was an endpoint measured in all clinical research.

Study Profile and Research Gaps

Studies explored how the dual-action profile of this biphasic human insulin is relevant in conditions where symptoms may vary in intensity. Pharmacokinetic research—studies that examine how the body handles the medicine—was evaluated in patients and volunteers. Research examined the patterns of the initial rapid action and the subsequent prolonged action.

A research limitation frame often noted in the evidence is the short follow-up duration (often 12 weeks), meaning long-term effects are not fully established. Furthermore, the core evidence relies heavily on surrogate endpoints ( HbA1c), with few data directly researching the rates of long-term diabetes-related complications (e.g., heart, kidney, or nerve issues).

Evidence in Special Populations

The research base includes studies where the medicine was observed in children and adolescents, but the available data for these groups remain insufficient compared to adults. This research provides context but research does not determine whether an individual will respond similarly for the younger population. Regarding older adults (ge 65 years old), these patients was observed in some clinical trials; however, subgroup findings are uncertain due to smaller sample sizes. Overall, research is ongoing, and data for certain groups remain insufficient.

Key Studies & References National Institutes of Health (NIH) - MedlinePlus Drug Information for Insulin

Frequently Asked Questions (FAQ)

Common questions about Actraphane (FAQ)

Q: Is Actraphane suitable for both Type 1 and Type 2 diabetes?

According to the official product information, Actraphane is indicated for the treatment of diabetes mellitus. Research evidence indicates that it has been studied and found effective for managing both Type 1 and Type 2 diabetes in adults.

Q: What is the difference between Actraphane and other types of human insulin?

Actraphane is officially described as a biphasic insulin. This means it is a fixed-ratio mixture containing a soluble (fast-acting) component and an isophane (intermediate-acting) component. This combination provides both a quick onset and a sustained effect in a single injection, which differs from insulins that contain only one component.

Q: What is the risk of low blood sugar (hypoglycemia) with Actraphane compared to other insulins?

Regulatory documents state that hypoglycaemia (low blood sugar) is the most frequently reported side effect of this medication, classified as Very Common (seen in more than 1 in 10 patients). However, the official product information does not provide specific comparative risk statistics against other insulin products.

Q: Does Actraphane interact with common pain relief medications?

Official regulatory information states that a class of drugs known as salicylates, which includes certain pain relievers, may reduce the amount of insulin required by the patient. No other common pain relief medicines are specifically listed as having an interaction that directly affects insulin needs.

Q: Does Actraphane contain any substances besides human insulin, like metacresol?

Yes, Actraphane is a suspension that contains the active substance (human insulin) and other inactive ingredients known as excipients. For example, it contains sodium. The full list of all inactive ingredients is detailed in the comprehensive official product information.

Q: Does changing my diet or exercise routine require a change in how Actraphane is used?

Official prescribing information indicates that a change in the required dose of Actraphane might require a change if you change your usual diet or if you undertake increased physical activity. Any dose modification is determined by a healthcare provider.

Q: Does Actraphane have a known interaction with pioglitazone or other diabetes tablets?

Yes, the regulatory profile states that oral antidiabetic medicinal products may reduce the patient's insulin requirement. Regulatory warnings state that if these medications are used together, individualized dose adjustment and intensified monitoring might be needed.

Q: Why might a patient with Type 2 diabetes be prescribed Actraphane?

Actraphane is typically prescribed when a regimen requires both a rapid initial effect to cover meals and a more prolonged effect for sustained control between meals. Its biphasic nature allows both of these actions to be achieved from a single product.

Q: What is the meaning of the percentage numbers sometimes associated with Actraphane (e.g., Actraphane 30/70)?

The numbers indicate the fixed ratio of the two types of insulin contained within the product. For instance, Actraphane 30 is composed of 30% fast-acting (soluble) insulin and 70% intermediate-acting (isophane) insulin. These ratios allow for tailoring the balance of action profiles.

Q: Why do some people experience localized swelling (oedema) when starting insulin like Actraphane?

Official documents list oedema (swelling or fluid retention) as a possible adverse reaction. This reaction may occur at the beginning of treatment and is generally of a temporary nature. The regulatory information does not detail the exact physiological reason for this temporary swelling.

Q: How quickly does the fast-acting part of Actraphane begin to work?

The official prescribing information indicates that the fast-acting (soluble) component starts to work quickly, usually within 30 minutes after the injection is administered.

Q: How long can the overall effect of one Actraphane injection last?

The overall duration of action is variable for each individual. Official sources state that the duration depends on several factors, including the dose administered, the injection site, and the patient's blood flow and level of physical activity.

Q: Is Actraphane the same as the insulin products Actrapid and Protaphane?

No, these products are different. Actrapid is a single-component fast-acting insulin, and Protaphane is a single-component intermediate-acting insulin. Actraphane is a biphasic mixture that combines both of these types of insulin.

Q: Can people who are switching from another brand of biphasic insulin expect a difference with Actraphane?

Official warnings note that changes in the insulin's brand (manufacturer) or type may require an adjustment of the Actraphane dose and timing. Regulatory information indicates that close blood glucose monitoring is usually employed during any transfer to a new brand.

Q: What happens if I miss a meal after taking Actraphane?

Regulatory safety warnings state that the omission of a meal after taking this medication may lead to hypoglycaemia (low blood sugar). This is because the fast-acting insulin component has already been given to cover the expected food intake.

Q: Is Actraphane available in different strengths, like 100 IU/ml?

Yes, Actraphane is described in regulatory documents as being available in different concentrations, such as 100 international units/ ml and 40 international units/ ml, depending on the presentation.

Q: Does taking Actraphane make driving or operating machinery unsafe?

Regulatory safety information states that a patient's ability to concentrate and react may be impaired as a result of hypoglycaemia (low blood sugar). This impairment constitutes a risk when driving a car or operating machinery. Precautions to avoid hypoglycemia are advised.

Q: How can a patient tell the difference between a high blood sugar symptom and a side effect of Actraphane?

Official safety documentation notes that the symptoms are distinct. Signs of Hypoglycaemia (low blood sugar) may include cold sweats, tremor, or confusion. In contrast, symptoms of Hyperglycaemia (high blood sugar) usually include increased thirst, frequent urination, dry mouth, or nausea.

Q: What should a person carry with them in case of low blood sugar while using Actraphane?

Regulatory safety advice states that hypoglycaemia can generally be corrected by immediate carbohydrate intake. Sources like glucose, sugar lumps, sweets, biscuits, or sugary fruit juice are used for correction. For severe episodes, glucagon or intravenous glucose is typically administered by a healthcare professional.

How should Actraphane be stored and disposed of?

Official Storage and Disposal Requirements

Actraphane storage is dictated by strict temperature and protection rules that differ for unopened and in-use products, as documented in official regulatory labeling.

Product Status	Required Storage Conditions
Unopened	Refrigerate between 2°C and 8°C. Store in the original package to protect from light. Do not freeze.
In-Use	Store at room temperature, not exceeding 25°C or 30°C. Keep the pen cap on to protect from light. Do not refrigerate.

In-use Actraphane has a stability period of 28 days (four weeks) from the date of first opening, after which it must be discarded. The medicine must be kept out of the sight and reach of children.

Disposal

Expired or unused Actraphane must be returned to a pharmacy or designated collection point for proper pharmaceutical waste disposal; it must not be discarded in household trash or wastewater. Used needles and syringes must be placed immediately into a puncture-resistant sharps container.

Actraphane